证券代码：000739 证券简称：普洛药业 公告编号：2025-41 普洛药业股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）第九届董事会第十四次会议通知于 2025 年 8 月 8 日以电子邮件及短信的方式发出，会议于 2025 年 8 月 18 日上午通过现场会议 的方式召开，会议应到董事 7 人，实到董事 7 人。会议由公司董事长祝方猛先生主持， 公司 3 名监事及 5 位高管列席了会议。本次会议的召开，符合《中华人民共和国公司法》 和本公司章程的规定。出席会议的董事经过审议表决，通过了以下议案： （二）公司董事会战略委员会变更为董事会战略与 ESG（环境、社会和公司治理） 委员会，成员由七名董事调整为五名，其中独立董事一名，由公司董事长担任主任委员； 董事会审计委员会成员将由五名董事调整为三名，且为不在公司担任高级管理人员的董 事，其中独立董事两名，由独立董事中会计专业人士担任主任委员；董事会提名委员会 成员将由五名董事调整为三名，其中独立董事两名，且由独立董事担任 ...

普洛药业股份有限公司 2025 年半年度报告全文 普洛药业股份有限公司 2025 年半年度报告 【2025 年 8 月 20 日】 1 普洛药业股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人祝方猛、主管会计工作负责人张进辉及会计机构负责人(会计 主管人员)石新跃声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请 投资者注意投资风险。 本报告第三节"管理层讨论与分析"中描述了公司未来经营中可能存在的 风险及应对措施，敬请投资者关注相关内容。 公司经本次董事会审议通过的利润分配预案为：以 2025 年 6 月 30 日公 司总股本 1,158,443,576 股扣减回购专用证券账户中股份 10,030,000 股后的 股本 1,148,413,576 股为基数，向全体股东每 10 股派发现金红利 3.4835 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-45 普洛药业股份有限公司 2025年中期利润分配方案 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、审议程序 2025 年 8 月 18 日，普洛药业股份有限公司（以下简称"公司"）第九届董 事会第十四次会议审议通过了《2025 年中期利润分配方案》。 本议案尚需提交公司股东大会审议。 根据《公司法》等法律法规和《公司章程》的有关规定，兼顾公司股东的即 期利益和长远利益，并综合考虑公司发展与投资者的利益诉求以及生产经营与财 务状况，公司在保证正常经营和持续发展的前提下，拟进行 2025 年中期利润分 配。具体分配方案如下： 以 2025 年 6 月 30 日公司总股本 1,158,443,576 股扣减回购专用证券账户中 股份 10,030,000 股后的股本 1,148,413,576 股为基数，向全体股东每 10 股派发 现金红利 3.4835 元（含税），共计派发现金红利 400,049,869.20 元（含税）， 剩余未分配利润结转以后年度分配，不送红股，也不以公积金转增股本。 公 ...

Core Viewpoint - The company, Pro Pharmaceutical (000739), is actively engaging in share repurchase and has established a strong presence in the pet medication market, with ongoing projects and a focus on enhancing shareholder returns. Group 1: Share Repurchase and Financial Performance - As of August 15, 2025, Pro Pharmaceutical's stock closed at 16.35 yuan, with a slight increase of 0.68% and a trading volume of 109,600 shares, amounting to a total transaction value of 179 million yuan [1] - The company has repurchased 10.03 million shares, totaling 143 million yuan, and plans to continue the repurchase based on market conditions and funding arrangements [2][3] Group 2: Pet Medication Projects - Pro Pharmaceutical has established long-term partnerships with several leading global pet medication companies, currently managing 49 pet medication projects, with both project numbers and sales revenue showing continuous growth [2] Group 3: Future Projects and Investor Relations - The company is in the design phase for a peptide workshop project with an investment of 300 million yuan, and specific investment strategies will be considered based on market and technological advancements [2] - The company is expected to disclose the progress of ongoing projects in the upcoming 2025 semi-annual report [2] - The company is open to suggestions regarding increasing dividend payouts and share buybacks to enhance investor confidence and returns [2][3]

每经AI快讯，有投资者在投资者互动平台提问：公司投资3个亿建造的多肽车间，预计何时建成投产？ 能否提前完成，预计年产值多少？ 普洛药业（000739.SZ）8月15日在投资者互动平台表示，目前，该项目尚处于设计阶段，后续公司将根 据市场和技术进展考虑具体投资策略。 （文章来源：每日经济新闻） ...

人民财讯8月15日电，普洛药业（000739）在互动平台表示，公司与多家全球领先的宠物药公司建立了 长期、密切的合作关系，截至目前，公司已有49个宠物药项目，项目数量和销售收入均保持持续增长态 势。 ...

金融界消息 截至2025年8月13日收盘，普洛药业（000739）报收于16.5元，上涨0.06%，换手率1.44%， 成交量16.71万手，成交金额2.74亿元。 资金流向方面，今日主力资金净流入2465.75万元，占比成交额8.99%。其中，超大单净流入855.60万 元、占成交额3.12%，大单净流入1610.15万元、占成交额5.87%，中单净流出流出1542.30万元、占成交 额5.62%，小单净流出923.45万元、占成交额3.37%。 普洛药业最新一期业绩显示，截至2025一季报，公司营业总收入27.30亿元、同比减少14.63%，归属净 利润2.49亿元，同比增长1.98%，扣非净利润2.06亿元，同比减少14.05%，流动比率1.505、速动比率 1.203、资产负债率44.93%。 天眼查商业履历信息显示，普洛药业股份有限公司，成立于1997年，位于金华市，是一家以从事医药制 造业为主的企业。企业注册资本116932.3576万人民币，实缴资本36306.776万人民币。公司法定代表人 为祝方猛。 通过天眼查大数据分析，普洛药业股份有限公司共对外投资了19家企业，参与招投标项目24次，知识 ...

Summary of Prolo Pharmaceutical Conference Call Company Overview - Prolo Pharmaceutical is engaged in the CDMO (Contract Development and Manufacturing Organization) business, which is experiencing rapid growth due to capacity expansion and enhanced R&D capabilities. The company expects revenue growth to remain above 25% over the next three years, making it a core driver of performance [2][4][31]. Key Business Segments CDMO Business - The CDMO business is entering a phase of accelerated growth, supported by an increase in project numbers and commercial orders. Significant capital investments in advanced production facilities have been made, enhancing production efficiency and R&D capabilities [4][31]. - Revenue from the CDMO segment reached 1.884 billion yuan in 2024, with a compound annual growth rate (CAGR) exceeding 20% since 2020 [14]. API and Intermediate Business - Prolo has over 30 years of experience in the API (Active Pharmaceutical Ingredient) and intermediate business, with plans to add 30 to 50 new API products in the next three years. The company aims to expand into the medical beauty and cosmetics sectors [2][5]. - The company’s API projects include 116 ongoing projects, with 22 in the commercialization stage [20]. Formulation Business - The formulation segment has benefited from national procurement policies, leading to steady revenue growth of around 10% over the next three years. The company plans to develop 25 new formulation projects annually [6][30]. Financial Outlook - In 2025, Prolo's apparent revenue may be pressured by weak antibiotic demand and the clearing of raw material trading business, but profits are expected to remain stable or grow slightly. From 2026 onwards, revenue is projected to grow by about 10%, with profits increasing by over 20%, primarily driven by the CDMO business [7][32]. - The overall gross margin is expected to improve as the CDMO revenue share increases and cost-reduction measures are implemented [13][32]. Market Dynamics - The raw material and intermediate business is facing intense competition, but the company is diversifying its product matrix to mitigate cyclical impacts. The company is also leveraging advanced production capabilities to enhance competitiveness [8][26]. - In the veterinary medicine sector, Prolo's API business, particularly with florfenicol, is expected to benefit from a recovery in livestock farming and price stabilization [3][27][28]. Strategic Initiatives - Prolo's future strategy includes enriching its product matrix with new API products and expanding into high-margin markets such as medical beauty and cosmetics [29]. - The company has established a comprehensive supply chain for its formulation business, which includes over 120 formulation varieties across various therapeutic areas [30]. R&D and Innovation - Prolo is focusing on advanced research areas such as fluid chemistry, synthetic biology, and high-activity compounds, supported by a robust R&D team [17][18]. Conclusion - Prolo Pharmaceutical is positioned for significant growth in the coming years, driven by its CDMO business and strategic expansion into new markets. The company’s proactive approach to enhancing production capabilities and diversifying its product offerings is expected to yield positive financial results and improve overall profitability [2][32].

Core Viewpoint - The company has indicated that it offers medications that can treat viral infections such as influenza and bacterial infections, addressing concerns raised by investors regarding the current outbreak of diseases like chikungunya and influenza [2] Company Summary - The company, Prolo Pharmaceutical (000739.SZ), has stated that its products, including Oseltamivir and Amantadine, are effective against influenza viruses [2] - The company also provides a range of antibiotics such as Cefixime, Cefdinir, and Amoxicillin/Clavulanate Potassium for infection treatment [2]

Core Viewpoint - The company has completed the enrollment for the phase III clinical trials of its semaglutide project, which targets both weight loss and diabetes management, and is currently in the follow-up phase of administration [1] Group 1 - The semaglutide project includes indications for both weight loss and diabetes [1] - All participants have been enrolled in the phase III clinical trials [1] - The current stage of the project involves follow-up after administration [1]